Hormone therapy for transgender patients
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Many transgender men and women seek hormone therapy as part of the transition process. Exogenous testosterone is used in transgender men to induce virilization and suppress feminizing characteristics. In transgender women, exogenous estrogen is used to help feminize patients, and anti-androgens are used as adjuncts to help suppress masculinizing features. Guidelines exist to help providers choose appropriate candidates for hormone therapy, and act as a framework for choosing treatment regimens and managing surveillance in these patients. Cross-sex hormone therapy has been shown to have positive physical and psychological effects on the transitioning individual and is considered a mainstay treatment for many patients. Bone and cardiovascular health are important considerations in transgender patients on long-term hormones, and care should be taken to monitor certain metabolic indices while patients are on cross-sex hormone therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stigma, Mental Health, and Resilience in an Online Sample of the US Transgender Population
Bockting, W. O., Miner, M. H., Swinburne Romine, R. E., Hamilton, A., & Coleman, E. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301241 · Cited by 1,540 · cited 1×
“However, in some situations when delay of therapy may lead to psychologic and cognitive trauma in a child, it may be appropriate to commence therapy earlier (34).”
BackgroundEndocrine Treatment of Transsexual Persons:An Endocrine Society Clinical Practice Guideline
Hembree, W. C., Cohen-Kettenis, P., Delemarre-van de Waal, H. A., Gooren, L. J., Meyer, W. J., Spack, N. P., Tangpricha, V., & Montori, V. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0345 · Cited by 1,026 · cited 3×
“As a result, there are strong recommendations against the use of ethinyl estradiol in transgender patients (8).”
BackgroundInfluentialA sex difference in the human brain and its relation to transsexuality
Zhou, J.-N., Hofman, M. A., Gooren, L. J. G., & Swaab, D. F. (1995) · Nature · doi:10.1038/378068a0 · Cited by 779 · cited 1×
“These data come from studies examining children with congenital genitourinary anomalies who were assigned gender at birth (1,2), as well as postmortem cadaveric studies (3).”
BackgroundA long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones
Asscheman, H., Giltay, E. J., Megens, J. A. J., de Ronde, W. (., van Trotsenburg, M. A. A., & Gooren, L. J. G. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-1038 · Cited by 570 · cited 1×
“This is no longer the case, as clinical evidence has showed a strong relationship between ethinyl estradiol and the incidence of deep venous thrombosis (13).”
ResultTransgender Health in Massachusetts: Results From a Household Probability Sample of Adults
Conron, K. J., Scott, G., Stowell, G. S., & Landers, S. J. (2012) · American Journal of Public Health · doi:10.2105/ajph.2011.300315 · Cited by 486
Sanchez, N. F., Sanchez, J. P., & Danoff, A. (2009) · American Journal of Public Health · doi:10.2105/ajph.2007.132035 · Cited by 418
Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People
Coleman, E. (2017) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-803506-1.00058-9 · Cited by 370
Reiner, W. G., & Gearhart, J. P. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa022236 · Cited by 347 · cited 1×
“These data come from studies examining children with congenital genitourinary anomalies who were assigned gender at birth (1,2), as well as postmortem cadaveric studies (3).”
BackgroundLong-Term Evaluation of Cross-Sex Hormone Treatment in Transsexual Persons
Wierckx, K., Mueller, S., Weyers, S., Van Caenegem, E., Roef, G., Heylens, G., & T’Sjoen, G. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02876.x · Cited by 335
World Professional Association for Transgender Health
(2016) · The SAGE Encyclopedia of LGBTQ Studies · doi:10.4135/9781483371283.n463 · Cited by 334
Wierckx, K., Elaut, E., Declercq, E., Heylens, G., De Cuypere, G., Taes, Y., Kaufman, J. M., & T'Sjoen, G. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0493 · Cited by 329
Long-Term Treatment of Transsexuals with Cross-Sex Hormones: Extensive Personal Experience
Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1809 · Cited by 308 · cited 1×
“Progestins are used by some providers, but should be used with caution as there is a theoretical risk of breast cancer associated with long-term exogenous progesterone use (15).”
BackgroundTestosterone therapy for transgender men
Irwig, M. S. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00036-x · Cited by 272
Meyer-Bahlburg, H. F. L. (2005) · Archives of Sexual Behavior · doi:10.1007/s10508-005-4342-9 · Cited by 247 · cited 1×
“These data come from studies examining children with congenital genitourinary anomalies who were assigned gender at birth (1,2), as well as postmortem cadaveric studies (3).”
BackgroundGiltay, E. J., & Gooren, L. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2913 · Cited by 230
Skeletal sexual dimorphism: relative contribution of sex steroids, GH–IGF1, and mechanical loading
Callewaert, F., Sinnesael, M., Gielen, E., Boonen, S., & Vanderschueren, D. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0209 · Cited by 222
Is Hormonal Therapy Associated with Better Quality of Life in Transsexuals? A Cross-Sectional Study
Gorin-Lazard, A., Baumstarck, K., Boyer, L., Maquigneau, A., Gebleux, S., Penochet, J.-C., Pringuey, D., Albarel, F., Morange, I., Loundou, A., et al. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02564.x · Cited by 185 · cited 1×
“Hormone therapy improves transgender patients’ quality of life (20).”
BackgroundNeuroreceptor imaging in depression
Savitz, J. B., & Drevets, W. C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.001 · Cited by 165 · cited 1×
“SERT expression has been shown to be reduced in individuals with major depression (22).”
BackgroundEndocrine Treatment of Male-to-Female Transsexuals Using Gonadotropin-Releasing Hormone Agonist
Dittrich, R., Binder, H., Cupisti, S., Hoffmann, I., Beckmann, M., & Mueller, A. (2005) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2005-865900 · Cited by 142 · cited 1×
“Through a negative feedback loop, exogenous therapy suppresses gonadotropin secretion from the pituitary gland, leading to a reduction in androgen production (12).”
BackgroundSpack, N. P. (2013) · JAMA · doi:10.1001/jama.2012.165234 · Cited by 141
Van Caenegem, E., Wierckx, K., Taes, Y., Dedecker, D., Van de Peer, F., Toye, K., Kaufman, J.-M., & T'Sjoen, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1187 · Cited by 139 · cited 1×
“Exogenous testosterone appears to have an anabolic effect on cortical bone and when dosed at physiologic levels, is adequate enough to avoid issues with bone demineralization in transgender patients (26).”
BackgroundAsscheman, H., T'Sjoen, G., Lemaire, A., Mas, M., Meriggiola, M. C., Mueller, A., Kuhn, A., Dhejne, C., Morel-Journel, N., & Gooren, L. J. (2014) · Andrologia · doi:10.1111/and.12150 · Cited by 132 · cited 2×
“Use of oral ethinyl estradiol appears to be strongly associated with cardiovascular events (30) and should therefore be avoided as a mainstay therapy for patients (31).”
BackgroundCostantino, A., Cerpolini, S., Alvisi, S., Morselli, P. G., Venturoli, S., & Meriggiola, M. C. (2013) · Journal of Sex & Marital Therapy · doi:10.1080/0092623x.2012.736920 · Cited by 121 · cited 2×
“Longitudinal studies also show positive effects on sexual function and mood (16,18).”
BackgroundNon-Prescribed Hormone Use and Barriers to Care for Transgender Women in San Francisco
de Haan, G., Santos, G., Arayasirikul, S., & Raymond, H. F. (2015) · LGBT Health · doi:10.1089/lgbt.2014.0128 · Cited by 117 · cited 1×
“In another study looking at 314 trans women in San Francisco, 49% were found to be taking hormones not prescribed by a clinician (37).”
BackgroundMepham, N., Bouman, W. P., Arcelus, J., Hayter, M., & Wylie, K. R. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12691 · Cited by 115 · cited 1×
“(36) found that one in four trans women self-prescribe cross-sex hormones, most commonly through the Internet.”
BackgroundNakamura, A., Watanabe, M., Sugimoto, M., Sako, T., Mahmood, S., Kaku, H., Nasu, Y., Ishii, K., Nagai, A., & Kumon, H. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0319 · Cited by 113
Progress on the road to better medical care for transgender patients
Gardner, I. H., & Safer, J. D. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000436188.95351.4d · Cited by 113 · cited 1×
“In addition, if a patient is at significant risk for osteoporosis, a baseline bone mineral density should be obtained (9).”
BackgroundInterpreting Laboratory Results in Transgender Patients on Hormone Therapy
Roberts, T. K., Kraft, C. S., French, D., Ji, W., Wu, A. H. B., Tangpricha, V., & Fantz, C. R. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.10.009 · Cited by 109 · cited 1×
“(33) looked at metabolic indices in male-to-female patients on hormone therapy in order to determine appropriate reference ranges.”
BackgroundWierckx, K., Elaut, E., Caenegem, E. V., de Peer, F. V., Dedecker, D., Houdenhove, E. V., & T'Sjoen, G. G. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0250 · Cited by 94 · cited 1×
“Despite these metabolic changes, and negative impact on potential risk factors for cardiovascular disease, no studies have found an increase in the occurrence of cardiovascular events such as myocardial infarction, deep vein thrombosis, and cerebrovascular events (16,29,30).”
BackgroundMueller, A., Zollver, H., Kronawitter, D., Oppelt, P. G., Claassen, T., Hoffmann, I., Beckmann, M. W., & Dittrich, R. (2010) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0030-1255074 · Cited by 93 · cited 1×
“Transgender women may be at higher risk for bone loss despite estrogen use (27).”
BackgroundColizzi, M., Costa, R., Pace, V., & Todarello, O. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12155 · Cited by 92 · cited 1×
“(23) looked at 70 transgender patients on hormone therapy and measured their cortisol levels as well as their perceived stress before and 12 months after starting hormone therapy.”
BackgroundHigh-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People
Kranz, G. S., Wadsak, W., Kaufmann, U., Savli, M., Baldinger, P., Gryglewski, G., Haeusler, D., Spies, M., Mitterhauser, M., Kasper, S., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.09.010 · Cited by 89 · cited 1×
“(21) have looked at the acute and chronic effects of estrogen and testosterone on serotonin reuptake transporter (SERT) binding in trans men and women.”
BackgroundManagement of female-to-male transgender persons: medical and surgical management, life expectancy
Gooren, L. J. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000064 · Cited by 63 · cited 1×
“As a result, many transgender men are shorter, have some degree of feminine subcutaneous fat distribution, and often have broader hips than biologic males (19).”
BackgroundEffects of high dose oestrogen therapy on circulating inflammatory markers
Wilson, R., Spiers, A., Ewan, J., Johnson, P., Jenkins, C., & Carr, S. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.01.009 · Cited by 59 · cited 1×
“After the age of 40, transdermal formulations are recommended as they bypass first pass metabolism and seem to be associated with better metabolic profiles (14).”
BackgroundEndocrine Treatment of Transsexual Persons: Extensive Personal Experience
Leinung, M. C., Fiore-Urizar, M., Patel, N., & Sood, S. C. (2013) · Endocrine Practice · doi:10.4158/ep12170.or · Cited by 57 · cited 2×
“Transl Androl Urol 2016;5(6):877-884 tau.”
BackgroundGooren, L. J., & Giltay, E. J. (2013) · Andrologia · doi:10.1111/and.12111 · Cited by 44 · cited 1×
“For instance, Gooren and Giltay (28) showed that long-term testosterone use reduced highdensity lipoprotein cholesterol and increased triglycerides as well as inflammatory markers.”
BackgroundCaenegem, E. V., Wierckx, K., Taes, Y., Dedecker, D., de Peer, F. V., Toye, K. R. C., Kaufman, J., & T'Sjoen, G. G. (2012) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000425652.26360.d7 · Cited by 5
Cited by
Impact of Hormone Therapy on Laboratory Values in Transgender Patients
SoRelle, J. A., Jiao, R., Gao, E., Veazey, J., Frame, I., Quinn, A. M., Day, P., Pagels, P., Gimpel, N., & Patel, K. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.292730 · Cited by 86
Rivera, S. (2022) · Journal of the American Psychoanalytic Association · doi:10.1177/00030651221104487 · Cited by 9
Urinary Tract Infection in a Transgender Male: A Primary Care Approach
Manion, A., & James, T. S. (2024) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2024.08.002
Metadata
- Authors
- Unger, C. A.
- Venue
- Translational Andrology and Urology
- Publisher
- AME Publishing Company
- Published
- 2016-12
- Volume
- 5
- Issue
- 6
- Pages
- 877-884
- ISSN
- 2223-4683 (ISSN-L)
- 2223-4691
- OpenAlex
- W2548724077
- Cited by
- 245
- References
- 37
- FWCI
- 22.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.